A State Of Truth

The Purpose Of This Page Is To Take Away Your Illusions

Posts for Tag: depopulation

UK Dependence on Palantir is Growing, at Great Public Cost

The growing presence of Palantir in the UK is no longer just a procurement story. The company now holds roughly £600 million in public contracts across the NHS, the Ministry of Defence, local councils and policing, while two petitions calling for ministers to sever ties with the firm have drawn more than 229,000 signatures. The concern is not limited to cost or outsourcing. It is that a company built in the worlds of intelligence, surveillance and military analysis is moving deeper into some of the UK’s most sensitive institutions at the same moment its leadership is becoming more explicit about the kind of technological order it wants to build. [Read More]

How DMSO Eases Cancer’s Hidden Burdens - Chemo, Pain, and Radiation Relief

DMSO is a remarkable naturally occurring substance that (provided it's used correctly) safely and rapidly improves a variety of conditions medicine struggles with - particularly chronic pain.

Many challenging infections such as shingles, herpes, chronic ear or dental infections, and osteomyelitis (discussed here). In turn, since I started this series, it struck a chord, and I have received over 2000 reports of remarkable responses to DMSO, and many readers have had for a variety of "incurable conditions." [Read More]

Four Out of Five Patients Reported Improvement or Stabilisation of Their Cancer After 6 Months of Treatment With Ivermectin and Mebendazole

The largest real-world human analysis of the use of a combination of ivermectin and mebendazole to treat cancer patients has been conducted.

It reveals that after just 6 months of treatment, 84.4% of cancer patients reported clinical benefit; nearly reported no evidence of disease or tumour regression, while over a third reported disease stabilisation.

“This means more than four out of five patients reported either improvement or stabilisation of their cancer,” Nicholas Hulscher writes. [Read More]